Article
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
All News
Article
Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival.
Article
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Article
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and
Dr. John Cush
Tweet
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq
Dr. John Cush
Tweet
Fatigue in SLE
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD
Dr. John Cush
Tweet
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj
Dr. John Cush
Tweet
Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU
Dr. John Cush
Tweet
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI
Dr. John Cush
Tweet
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed vs unexposed: overall MCM 8.2% v 7%; aRR 0.99). MCMs not incr = MSK, CV, CNS, cleft palate, GI, GU, nonsignif MSM aRR from 0.77- 1.05 https://t.co/ytYhBFl44o https://t.co/1fq4D1KykM
Dr. John Cush
Tweet
In this week's RheumIQ quiz: An RA patient has a current or new cancer. With which cancer should you avoid/stop the use of a TNF inhibitor? See if you got it right at https://t.co/DTabBEfjj9 https://t.co/tVYUEjAPy3
Dr. John Cush
Tweet
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP https://t.co/lCZNoTh9fv
Dr. John Cush
Tweet
ANCA-Assoc. Vasculitis has great Rx optionis, BUT still no reliable biomaker to predict relapse or renal outcomes, this includes IL-6. But there is hope for CD163 in the future. https://t.co/lFyfTPj5vG https://t.co/wLfOPz76JC
Dr. John Cush
Tweet
Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+ more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/9i3BBGA0uu
Dr. John Cush
Tweet
Meet the RheumNow #EULAR2026 Reporting Team
Delivering real-time insights from the forefront of rheumatology:
🩺 Dr. Antoni Chan (@synovialjoints)
🩺 Dr. Mrinalini Dey (@DrMiniDey)
🩺 Dr. Jiha Lee (@JihaRheum)
🩺 Dr. Aurelie Najm (@AurelieRheumo)
🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush
Tweet
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
https://t.co/R1wbJHXwjD https://t.co/65HtG0Te94
Dr. John Cush
Tweet
Lupus Mortality Risk in Young Women
New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant https://t.co/2FSINr6gZN
Dr. John Cush
Tweet
Branebrutinib (Bruton's tyrosine kinase inhibitor) was studied in phase 2 RCT of 85 RA pts for 12 weeks and was safe but failed to achieve an ACR50 response (19% BTK vs 33% PBO; p=0·16). https://t.co/gTjLJm9iIW https://t.co/GN9p1P8ZNJ
Dr. John Cush
Tweet
ArthritisPower Registry (now PatientSpot) survey study of 351 RA pts (age 60, F 84%); reported 439 nonserious infx. 27% total infx, 14%w/ MD visist & Abx. Infx incr w/ GC ≥10 mg/d (OR 1.94), but Biologics & JAKi not assoc. w/ greater NSIE risk vs cs DMARDs https://t.co/bHqFnoY0Ud
Dr. John Cush
Tweet
Registry of 587 #SLE pts. 30% were RNP+ --> more dz activity than RNP- (SLEDAI-2 8.0 vs 4.0) and more Rx use (daily GC 6.8 vs 3 mg). RNP+ more renal, skin & serologic activity & less likely to LLDAS (20% vs 32%) or REM (12% vs 23%). RNP + 18-fold more likely to be Sm+ https://t.co/3J0Uew48OS
